Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP. We aimed to evaluate the biosimilar CT-P13 (Remsima) in terms of efficacy, tolerance, and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2022-12-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Subjects: | |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S266134172250002X |